Gene Editing and Gene Therapy

Please click here to register

November 17, 2022 – Virtual Event

GenomeWeb and The Precision Medicine Leaders’ Summit present the

Gene Editing and Gene Therapy

as part of our comprehensive coverage of the Precision Medicine Continuum

Join us at the Gene Editing and Gene Therapy Virtual Summit to hear how advances in gene editing and gene therapies are transforming medicine and delivering precise, personalized care. The event will take place on November 17, 2022, from 10:00 am to 2:00pm EST.

Gene editing and gene therapies promise to serve as the foundation of precision medicine, treating disease at the molecular level by transferring new or modified genetic material to a patient’s cells. Over the last decade, cell and gene therapies have advanced for oncology, inherited disease, metabolic diseases, and musculoskeletal and immunological disorders. The Food and Drug Administration has so far approved more than 20 cell and gene therapies and estimates that by 2025 it will approve 10 to 20 such therapies per year. But there are still obstacles in the way of broad implementation of gene editing and gene therapies. In particular, improvements are needed in vector biology and manufacturing in order to expand the availability of these treatments. The development of safe, yet cost-effective, delivery systems is a key challenge for the field.

Attend the Gene Editing & Gene Therapy Virtual Summit to hear the latest efforts to overcome these obstacles and usher gene editing and gene therapy into the forefront of precision medicine. Speakers will address advances in nucleic acid engineering, gene editing, vector biology, manufacturing, and other areas that promise to accelerate development of the field.

Topics to be discussed:

  • The regulatory landscape for cell and gene therapies
  • Advances in vector biology and viral vector manufacturing
  • Best practices in cell therapy logistics
  • Gene therapy for monogenic diseases
  • Clinical trial design for cell and gene therapy
  • R&D considerations for cell and gene therapies in oncology and beyond (infectious disease, inherited disease, metabolic disease, ophthalmology, immunological disorders, neurology)
  • From autologous to allogeneic: Forging a path to off-the-shelf CAR-T therapy
Register Now